Related Experiment Video
Updated: Jun 14, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression
Linlang Guo1, Yongguang Liu, Yifeng Bai
1Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. linlangg@yahoo.com
Abstract:
MicroRNAs (miRNAs) are now known to play important roles in the regulation of gene expression for developmental timing, cell proliferation and apoptosis. Therefore, it is likely that they also modulate sensitivity and resistance to anti-cancer drugs. To better understand the molecular mechanisms of multidrug resistance in SCLC and identify novel molecular markers, we evaluated the expression of 856 miRNAs and approximately 22,000 genes using miRNA microarray and cDNA microarray in cellular models of SCLC which were widely used as sensitive (NCI-H69) and resistant cell lines (NCI-H69AR) to chemotherapy. We also analysed the correlations between miRNA and mRNA expression patterns. Further studies were tested to determine whether the differentially expressed miRNAs were involved in multidrug resistance in SCLC. Our results showed that 61 miRNAs are presented significantly (>3-fold) including up-regulation of 24 miRNAs and down-regulation of 37 miRNAs. Among these miRNAs, 48 of 61 differentially expressed miRNAs were firstly reported to be closely associated with drug resistance and 37.7% (24/61) of miRNA genes were organised as 10 clusters in total 61 significantly expressed miRNAs. We also found that only 27 of 69 miRNAs were significantly correlated with 604 of 21,522 70 mRNA transcripts by MAS database. The sensitivity to anti-cancer drugs Cisplatin, Etoposide and Doxorubicin greatly increased or reduced following transfection of the drug-resistant H69AR cells with the mimics or antagomirs of miR-134, miR-379 and miR-495, respectively. miR-134 increases the cell survival by inducing G1 arrest in H69AR cells. MRP1/ABCC1 is negatively regulated by miR-134 and down-regulation of MRP1/ABCC1 at the protein level largely correlates with elevated levels of miR-134 in H69AR cells. Our results support for the first time a substantial role for miRNAs in multidrug resistance in SCLC. miR-134 could be a causal factor of the down-regulation of MRP1/ABCC1 in H69AR cells. These findings provide valuable information for potential utility of these miRNAs as specific diagnostic biomarkers and novel therapeutic approaches for drug resistance of SCLC.
Insights
MicroRNAs (miRNAs) play a key role in drug resistance in small cell lung cancer (SCLC). Researchers identified specific miRNAs, like miR-134, that can alter chemotherapy sensitivity and serve as potential biomarkers for SCLC treatment.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- MicroRNAs (miRNAs) are crucial regulators of gene expression, influencing cell proliferation, apoptosis, and potentially drug sensitivity.
- Understanding the role of miRNAs in multidrug resistance is vital for developing effective cancer therapies.
Purpose of the Study:
- To investigate the role of microRNAs (miRNAs) in multidrug resistance in small cell lung cancer (SCLC).
- To identify novel molecular markers and therapeutic targets for overcoming chemotherapy resistance in SCLC.
Main Methods:
- Utilized miRNA and cDNA microarrays to analyze the expression of 856 miRNAs and ~22,000 genes in sensitive (NCI-H69) and resistant (NCI-H69AR) SCLC cell lines.
- Performed correlation analysis between miRNA and mRNA expression patterns.
- Investigated the functional impact of specific miRNA mimics and antagomirs on drug sensitivity and cellular processes.
Main Results:
- Identified 61 significantly differentially expressed miRNAs, with 48 novel associations with drug resistance.
- Demonstrated that manipulating miR-134, miR-379, and miR-495 levels altered sensitivity to Cisplatin, Etoposide, and Doxorubicin.
- Found that miR-134 promotes cell survival by inducing G1 arrest and negatively regulates MRP1/ABCC1, a key drug resistance factor.
Conclusions:
- MicroRNAs play a substantial role in multidrug resistance in SCLC.
- miR-134 is implicated as a causal factor in MRP1/ABCC1 down-regulation, contributing to drug resistance.
- These findings highlight the potential of miRNAs as diagnostic biomarkers and therapeutic targets for SCLC drug resistance.
More Related Videos
08:49Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
09:06MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
Published on: October 7, 2025